ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0115

Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry
Abstract Number: 0116

Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Abstract Number: 0117

Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Abstract Number: 0118

Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Abstract Number: 0119

Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Abstract Number: 0120

Vascular Liver Disorders in Patients with Antiphospholipid Syndrome: A Retrospective National Multicentre Study
Abstract Number: 0121

Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
Abstract Number: 0122

Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Abstract Number: 0123

The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)
Abstract Number: 0124

Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates
Abstract Number: 0125

Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome
Abstract Number: 0126

Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data
Abstract Number: 0127

Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Abstract Number: 0128

Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study
Abstract Number: 0129

The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.